Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

- PMLiVE

EMA clears GSK’s diabetes therapy Eperzan

Once-weekly GLP-1 therapy will line-up against Victoza and Byetta

- PMLiVE

GSK withdraws melanoma combo in EU

EMA says it needs more data to review Mekinist and Tafinlar

- PMLiVE

GSK’s cancer vaccine flunks another trial

MAGE-A3 fails to improve survival in lung cancer patients

- PMLiVE

GSK to hire doctors as product champions

Will use in-house personnel instead of external speakers to present information

Bristol-Myers Squibb (BMS) building

BMS strikes $350m deal to boost its immuno-oncology pipeline

Will collaborate with US biotech Five Prime Therapeutics

- PMLiVE

Novo Nordisk will build $100m facility in Denmark

Bagsvaerd site will support growing diabetes pipeline

- PMLiVE

GSK set to file severe asthma candidate by year-end

Mepolizumab reduces frequency of exacerbations in late-stage trial

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

Trial boost for Novo’s IDegLira ambitions

Company says drug shows weight benefits and low risk of hypoglycaemia

- PMLiVE

GSK raises stake in Indian subsidiary

Company eyes long-term growth of market

- PMLiVE

Death of a salesman

Will people communicate the same way if their results are not being measured?

Bristol-Myers Squibb (BMS) building

BMS’ novel HIV drug clears phase II trial

Entry inhibitor BMS-660368 moves closer to first-in-class approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links